Home > Insider Trading > Filing (0001193805-23-001317)

Filing Details

Accession Number:: 0001193805-23-001317
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-09-22 21:21:02
Reporting Period:: 2023-09-20

Accepted Time:: 2023-09-22 21:21:02
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1262104	Mei Pharma Inc.	MEIP	Pharmaceutical Preparations (2834)	510407811

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1491069	Ross Bruce Winson	16000 Dallas Parkway Suite 800 Dallas TX 75248	No	No	Yes	No
1491072	Anson Funds Management Lp	16000 Dallas Parkway Suite 800 Dallas TX 75248	No	No	Yes	No
1491073	Anson Management Gp Llc	16000 Dallas Parkway Suite 800 Dallas TX 75248	No	No	Yes	No
1581079	Anson Advisors Inc.	155 University Avenue Suite 207 Toronto A6 M5H 3B7	No	No	Yes	No
1585167	Moez Kassam	111 Peter Street Suite 904 Toronto A6 M5V2H1	No	No	Yes	No
1962354	Amin Nathoo	155 University Avenue Suite 207 Toronto Z4 M5H 3B7	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-09-20	120,000	$6.01	782,528	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2023-09-21	33,600	$6.46	816,128	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes

Footnotes

The filing of this Form 4 shall not be construed as an admission that Anson Funds Management LP ("Anson"), Anson Management GP LLC, the general partner of Anson ("Anson GP"), Bruce R. Winson, the manager of Anson GP, Anson Advisors Inc. ("Anson Advisors"), Amin Nathoo, a director of Anson Advisors, or Moez Kassam, a director of Anson Advisors, is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or otherwise the beneficial owner of any of the shares of Common Stock, $0.00000002 par value (the "Common Stock"), of MEI Pharma, Inc. (the "Issuer") purchased by Anson Investments Master Fund LP, Anson East Master Fund LP and Anson Opportunities Master Fund LP (collectively, the "Funds"), each advised by Anson and Anson Advisors.
Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
Anson and Anson Advisors hold indirectly 816,128 shares of Common Stock of the Issuer through the Funds, for which Anson and Anson Advisors are the Investment Advisors. Anson GP and Bruce R. Winson report the Common Stock held indirectly by the Funds because, as the general partner of Anson and the manager of Anson GP, respectively, at the time of purchase, they controlled the disposition and voting of the securities. Mr. Nathoo and Mr. Kassam report the Common Stock held indirectly by the Funds because, as the directors of Anson Advisors, at the time of purchase, they controlled the disposition and voting of the securities.